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Abstract
Diabetic retinopathy (DR) is one of the most frequent microvascular  
complications of diabetes. A large body of evidence supports the role of inflam-
mation in the development and progression of DR. Currently, DR is diagnosed 
based on the presence of morphological lesions detected on fundus examination. 
Yet, there are other laboratory or imaging biomarker whose alteration precede 
DR lesions. This chapter will first briefly explain the role of inflammation in DR 
pathogenesis and will analyze the molecules involved. Further, it will discuss 
significant and recent studies that analyzed local laboratory or imaging inflam-
matory biomarkers in different DR stages. It will then focus on several potential 
inflammation-targeting therapies which proved to be effective in animal or 
human studies. Validation of these reviewed biomarkers would allow the iden-
tification of patients who do not respond to the current available treatment and 
could benefit from an adjunctive therapy.
Keywords: diabetic retinopathy, inflammation, biomarker, retinal imaging,  
anti-inflammatory therapy
1. Introduction
Diabetus mellitus (DM) is an important public health issue, with a constantly 
growing prevalence from 4.7% in 1980 to 8.5% in 2014 [1]. In 2019, 463 million adults 
between 20 and 79 years had DM [2]. Diabetic retinopathy (DR) is one of the most 
frequent microvascular complications of diabetes. Most type 1 DM (T1DM) patients 
develop DR only after 5 years or even more from the onset of DM, but after 20- year 
history of disease, 99% present a form of DR [3]. On the contrary, for type 2 DM 
(T2DM) patients, DR may be present even from the diagnosis, while after 20 years 
of T2DM, 60% of the patients develop DR [3]. Currently, DR staging is performed 
depending on the presence of clinical ocular biomarkers, such as microaneurysms, 
hemorrhages, soft or hard exudates, macular oedema and new vessels. The treatment 
for DR targets especially the severe non-proliferative diabetic retinopathy (NPDR) or 
proliferative diabetic retinopathy (PDR) stage and diabetic macular oedema (DME). 
The therapeutic options are intravitreal injections with anti-VEGF agents, cortico-
steroids injections, retinal laser or surgery such as pars plana vitrectomy (PPV). A 
large body of evidence supports the role of inflammation in the development and 
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progression of DR. There is evidence that low-grade subclinical inflammation is 
responsible for many of the characteristic vascular lesions of DR [4]. In this review 
we provide an overview of several local inflammatory biomarkers of DR laboratory 
and retinal imaging together with anti-inflammatory therapeutic options.
2. Inflammation and diabetic retinopathy
Inflammation is defined as the body’s mechanism of self-defense against patho-
gens. In this complex process, mediators such as pro-inflammatory cytokines, 
chemokines and adhesion molecules are involved. They initiate the interaction 
between the endothelium and leukocytes and consequently induce the migration of 
leukocytes towards the injured or infected tissue [5]. Although acute inflammation 
is considered beneficial, a chronic and dysregulated one produces harmful effects, 
being known to be involved in diseases such as rheumatoid arthritis, multiple 
sclerosis and atherosclerosis [5].
Lutty et al. were the first who reported an increased neutrophil number per 
square millimeter in both retinal and choroidal vessels in DR patients [6]. Moreover, 
they continued the study of neutrophils in diabetic monkeys and found an associa-
tion between the accumulation of neutrophils and capillary closure [7]. Further 
studies found evidence that capillary occlusion and intraretinal neovascularization 
are associated with the attachment of neutrophils and monocytes [8], while the 
level of leukocytes adherence to the retinal vasculature, known as leukostasis, 
is associated with the progression of DR [9]. Recent findings implicate that an 
increase of ICAM-1 and integrins at the level of endothelial cells and leukocytes is 
responsible for the increase in leukostasis, while ICAM-1 blocking and CD18 dele-
tion decreases the leukostasis induced by DM [10, 11]. Microglial cell is a resident 
macrophage distributed throughout the retina, which releases inflammatory 
cytokines such as TNF-α after being activated [12].
There are several processes in DR pathogenesis in which inflammation is 
involved:
1. vessel leakage: retinal endothelial permeability is induced by TNF-α, but is 
successfully prevented by PKCζ inhibitor [13]. After TNF-α was blocked with 
Etanercept, a soluble TNF-α receptor, the activation of NF-κB was inhibited 
and blood retinal barrier (BRB) breakdown was prevented [14]. Similarly, 
VEGF is directly involved in the breakdown of inner BRB, being proved that 
after blocking ICAM-1, the leukostasis is reduced but also VEGF induced  
vascular leakage is blocked [15].
2. vessel closure: IL-1β and TNF-α increase caspase 3 activity and induce  
endothelial cell apoptosis [16, 17].
3. pathological neovascularization: New vessels’ formation is induced by leuko-
cytes by interfering in the releasing of pro-angiogenic factors, such as VEGF, 
angiopoietin 1, basic fibroblast growth factor, transforming growth factor and 
platelet derived factor. All these agents promote recruitment of endothelial 
progenitor cells and enhance the migration, proliferation and survival of the 
pre-existing endothelial cells [17].
4. retinal neuronal death: TNF-α, IL-1β, reactive oxygen species (ROS) and 
excessive nitric oxide (NO) released by leukocytes during inflammation are 
involved in retinal neuronal cell death [5].
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DM causes increased systemic and local production of numerous inflammatory 
molecules involved in DR onset and development.
3. Inflammatory biomarkers
A biomarker has been defined as “a biological molecule found in blood, or other 
bodily fluids, or tissue which represents a sign of a normal or abnormal process 
of a condition or disease” [18]. Due to the rapid advancement in engineering, 
methodology and equipment, researchers are able to generate large amounts of data 
analyzing only small amounts of samples, using mass spectrometry techniques. 
In DR studies, several kinds of samples were used, such as tear, cornea, aqueous 
humor (AH), lens, vitreous humor (VH), retina and serum [19]. Although VH is in 
direct contact with the retina, it requires a highly invasive procedure, whereas the 
tears can be collected using non-invasive methods but interact indirectly with the 
retina [19].
3.1 Local laboratory biomarkers
3.1.1 Tears
The tears are composed of an aqueous solution of water, lipids, proteins and salt. 
The major proteins are lactoferrin, lysozyme, serum albumin, secretory immuno-
globin A, lipocalin and lipophilin [20]. One study identified 1526 proteins using 
protemics approaches, most of them being shown to respond to insults such as 
cataract surgery or diseases like DM [21, 22]. Mainly because it contains proteins in 
high concentration (about 8 μg/μl) and it is easy to collect, tears have been a fluid of 
interest for many studies [21]. Herber et al. was one of the first to demonstrate that 
DM patients’ tear composition is different from control subjects [23]. Azzaralo et al. 
found increased levels of lactotransferin, also known as lactoferrin, a glycoprotein 
with immunomodulatory, anti-microbial and anti-tumor effects [24]. Increased 
levels of monocyte chemoattractant protein-1 (MCP-1) were also identified in DM 
with or without DR. A previous study demonstrated elevated Interleukin-1 receptor 
anatagonist (IL-1ra) levels, which represent an anti-inflammatory factor inhibiting 
pro-inflammatory activity of IL-1beta [25]. A positive correlation between IL-6 
levels and DR stage was found. IL-6 is involved in synthesis and the release of acute 
phase reactants and matrix metalloproteinase 9 (MMP-9), decreased tear produc-
tion, having also a role in the release of IL-1β [26]. TNF-α is a cytokine able to 
induce the disruption of BRB by loosening the tight junctions between endothelial 
cells and between RPE cells, with a role in the leukocytes adhesion to the endothe-
lium [13]. TNF-α level was increased in patients with PDR (13.5 pg./mL) compared 
to NPDR (2.8 pg./mL) [27]. The tear sample can be obtained using two techniques: 
the direct one using aspiration with the help of a micropipette or a microcapillary 
tube placed in the inferior fornix, or the indirect one, with the help of a Schirmer 
test strip or cellulose sponge.
3.1.2 Aqueous humor
Aqueous humor (AH) is produced by the ciliary body epithelium and represents 
the fluid in the anterior chamber of the eye. It is involved in the removal of meta-
bolic wastes, in ocular immunity, it supplies oxygen and nutrients, and has a role 
in refraction. AH is composed of water, electrolytes and proteins, which although 
are present in relatively low concentrations compared to blood serum, are vital in 
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the maintenance of anterior segment homeostasis. AH is not in direct contact with 
the retina but proteins released from it can enter AH either through disrupted BRB, 
cilio-retinal circulation or through diffusion from the VH and the VH-AH barrier 
[28]. Proteomic analysis studying AH from patients with DR compared to subjects 
without DM, found several proteins associated with PDR like apolipoprotein 
A-I (APOA1), apolipoprotein A-II (APOA2), apolipoprotein A-IV (APOA4), and 
α-1-acid glycoprotein 1 (ORM1) [29] as well as selenoprotein P (SELENOP), and 
cystathionine β-synthase (CBS) [28].
IL-23 levels were increased in PDR patients, and IL-17 was also higher in NPDR 
and PDR compared to control subjects as shown by Wang et al. in 625 patients with 
T2DM [30]. IL-17 is a powerful pro-inflammatory cytokine capable of mobiliz-
ing neutrophils and inducing the secretion of IL-6 and IL-8 prostagladin E2 [30]. 
Regarding IL-23, it stimulates Th17 cells to secrete IL-17, which further increases the 
cycle of inflammation.
Concerning IL-10, the cytokine with immunosuppresive properties, capable 
of attenuating the antigen-presenting ability of APC, studies found contradic-
tory results: decreased concentrations in DR compared to NPDR by Cheung et 
al. and Zhang et al., contrary to Hu et al. who reported increased levels [30]. It 
was also suggested that IL-10 levels could be correlated with central subfield 
thickness (CST), one study reporting higher IL-10 concentration in PDR 
(224,79 pg./mL) that in the control group (160/14 pg./mL) [31]. TGF-beta is 
involved in the differentiation of activated CD4+Th0 cells into Treg cells, but it 
is also involved in promoting differentiation of CD4+Th0 cells into Th17 cells in 
combination with IL-23 [32]. Zhang et al. found elevated and stable TGF-beta 
levels in DM compared to control [30].
Myonectin inhibits the inflammatory response triggered by lipopolysaccharide 
in macrophages and in myonectin-knockout mices, in which the proinflammatory 
gene expression was identified. Previous studies demonstrated decreased myo-
nectin concentrations in AH belonging to T2DM especially with PDR but also in 
NPDR compared to control subjects [33, 34]. In refractory DME, IL-2, IL-8, PIGF 
and VEGF were found elevated but only IL-8 was correlated with responsiveness, 
exhibiting higher levels in the refractory group [31]. This result is supported by 
Jeon et al., who observed that after injecting triamcinolone intravitreally to patients 
unresponsive to IVB, the effect was positive while the efficacy was associated with 
IL-8 levels in the AH [35].
IL-6, another proinflammatory cytokine was found elevated in PDR and DME 
patients. Additionally, it induces VEGF expression, being involved in the break-
down of BRB and thus being involved in the pathogenesis of earlier stages of NPDR 
[36]. IL-6 is considered as a driving force because it changes the overall cytokine 
profile in the AH of DM patients. Moreover, the level of VEGF in AH was strongly 
correlated with VEGF level from the VH [37].
IFN-α is a known angiogenic inhibitor, with a protective role against retinal 
damage in diabetes. Cheung et al. found reduced IFN-α levels in DM patients 
compared to control subjects [38].
MCP-1 level in AH is believed to be a predictor for a worse visual acuity outcome 
of PDR patients after vitrectomy, while there was no significant correlation between 
VEGF levels and BCVA, as noted by Lei et al. [39]. MCP-1 stimulates the recruit-
ment and activation of monocytes and macrophages which further leads to higher 
microvascular permeability or ischemia from vessel occlusions. A few studies have 
investigated the effect of intravitreal triamcinolone [40] or dexamethasone implant 
[41] on the intraocular inflammatory cytokines and concluded that both drugs 
could significantly decrease the level of MCP-1 in the AH.
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Samples from AH are collected through a paracenthesis from patients under-
going cataract surgery, trabeculectomy or from post-mortem eyes. The volume 
collected ranges from 100 to 150 μL. The samples from living patients are more 
useful since the profile from post-mortem eye is different due to the accumulation 
of metabolic waste [26].
3.1.3 Vitreous humor
The vitreous humor is the gelatinous component of the posterior segment of the 
eye that gives its spherical shape. In addition to its role in structural support, the trans-
parent nature of the vitreous body aids in light transmission to the retina. Because of 
its avascular nature, much of the proteins found in VH are derived from the retina 
itself [28]. Several proteins in the VH have been identified as biomarkers for differ-
ent stages of DR, like components of the acute phase response, coagulation pathway, 
complement system and other inflammatory pathways (e.g., VEGF, amyloid-β A4 
protein, metalloproteinase inhibitor 1, kininogen-1) [19].
Pigment epithelium-derived factor (PEDF) is a negative regulator of inflam-
matory processes, with lower levels in VH from DR patients compared to NDR. 
This finding suggest that beside an increase in proinflammatory cytokines, there 
is also a decrease in the anti-inflammatory ones [42]. Clusterin, a protein involved 
in the regulation of complement cascade, was found decreased in DR patients 
[43]. One of its function consists in an anti-inflammatory protection for the BRB 
[44]. Kallikrein, a known central component of pro-inflammatory kallikrein-kinin 
system, was found elevated in the VH from DR patients [45].
Anti-VEGF agents such as bevacizumab did not have a significant effect on VH 
inflammatory proteins as shown by Loukovaara et al. [46], as opposed to Zou et al. 
who studied VH proteome from patients treated with anti-VEGF agent ranibizumab 
and found decreased VEGF levels as well as a decrease in complement activation 
protein, acute inflammatory response and platelet degranulation [47]. Similarly, 
photocoagulation reduced the levels of pro-inflammatory protein osteopontin 
(SPP1), as shown by Wei et al. [48].
When exposed to intravitreal injection of IL-1β, retinal capillary endothelial 
cells degenerate [49], while co-administration of IL-1β, together with high concen-
trations of glucose, disrupt the RPE cells [50]. Increased levels of IL-1β were found 
in the VH collected from diabetic patients compared to control [51], underlining its 
role it the DR-related inflammatory processes.
IL-8, responsible for activating neutrophils and T Lymphocytes, together 
with IL-6, a chemokine responsible for increased endothelial cell permeability by 
rearranging actin filaments and changing the shape of endothelial cells, were both 
found elevated in VH of PDR patients [52]. Their origin does not seem to be the 
serum, since higher levels were found in the vitreous, suggesting that macrophages, 
RPE cells, glial cells or monocytes from the vitreous of PDR patients, could produce 
citokines [53]. IL-10, another anti-inflammatory cytokine, with the ability of deac-
tivating macrophages, was not found to be increased in PDR patients, the author 
of the study suggesting the lack of a counter balanced by the anti-inflammatory 
cytokines [54].
MCP-1, with its known role in promoting leukocyte recruitment and inducer of 
angiogenesis and fibrosis, was found elevated in DR VH, with levels being higher 
than in the serum [55]. Hyperglycemia seems to increase the formation of MCP-1 
from RPE cells, retinal vascular endothelial cells and Muller’s cells [56]. This finding 
further encouraged that MCP-1 gene polymorphism to be proposed as a potential 
risk factor for DR [57].
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Stromal cell-derived factor-1 (SDF-1) is upregulated in damaged tissues and as a 
response, it mobilizes progenitor cells to promote repair [58]. Together with VEGF, 
it promotes endothelial progenitor cells from the bone marrow to the ischemic 
retina [59]. Butler et al. found increased SDF-1 concentrations in VH from DME or 
PDR patients, and moreover the increase was correlated with disease severity [60].
Extracellular High-Mobility Group Box-1 Protein (HMGB1) as a proinflamma-
tory cytokine, leads to overexpression of TNF-α, MCP-1, ICAM-1, through activa-
tion of NF-β [61]. In addition, El-Asrar reported elevated levels of HMGB1 in VH 
belonging to PDR patients. They further reported that HMGB1 and its receptor for 
advanced glycation products (RAGE) are expressed by vascular endothelial cells 
and stromal cells in PDR fibrovascular epiretinal membranes [61].
Tumor Necrosis Factor-α (TNF-α) was found elevated in VH from DM patients, 
with a higher vitreous/serum ratio [51]. In addition, TNF-α was also found 
expressed in vascular endothelial and stromal cells in epiretinal membranes belong-
ing to PDR eyes [62].
ICAM-1 levels in PDR were found increased, especially in active PDR compared 
to inactive PDR [61]. ICAM-1 was highly expressed in retinal and choroidal blood 
vessels, as well as in fibrovascular membranes, and its expression seems to correlate 
with the number of migrated neutrophils in the retina and choroid [6]. When 
ICAM-1 blocking was obtained, the leukostasis, endothelial cell death and also the 
vascular leakage in the retinal vessels was diminished.
When retinal capillary endothelial cells were exposed to high concentration of 
glucose, TNF-α or IL-1β, they produce the membrane-bound form of vascular adhe-
sion protein-1(VAP1) and release the soluble vascular adhesion protein 1 (sVAP-1) 
[63]. Its role consists in leukostasis and leukocyte entrapment. High levels of sVAP-1 
were found in the serum and VH of patients with PDR [64].
Samples from VH are collected through vitreous taps from patients that under-
went PPV or after intravitreal injections. Simo et al. raised the problem of con-
founding factors that could lead to misinterpretation of result. Vitreous hemorrhage 
could induce a massive influx of serum proteins. Similarly, the disruption of BRB 
also leads to increased protein levels in VH. The first problem could be solved by 
rejecting samples with hemoglobin >5 mg/mL, while the second one, by correcting 
the intravitreal concentration of peptide under study for total vitreal proteins or 
calculating the vitreous/plasma ratio [56].
3.2 Imaging retinal biomarkers
3.2.1 Hyperreflective retinal foci
These lesions are found under the name of hyperreflective foci, dots or spots. 
Hyperreflective retinal foci (HRF) have been first described in wet AMD but they 
were also noted in retinal vein occlusion, MacTel type 2, central serous retinopathy, 
retinitis pigmentosa, Stargardt disease and Best disease. Different pathogenetic ori-
gins were hypothesized: initially they were considered precursor of hard exudates 
or lipid-laden macrophages [65], representing subclinical features of lipoprotein 
extravasation that were not observed on clinical examination, fundus photography, 
or fluorescein angiography, due to their small size [66]. In contrast to the previous 
studies, Lee et al. proposed that HRF represent activated microglial cells since they 
determined the presence of increased soluble CD14 in the AH. Soluble CD14 seems 
to be released by activated microglial cells [67, 68]. Other theories assumed that 
HRF represent debris of photoreceptors or RPE hyperplasia [65, 66].
HRF are initially present in the inner retinal layers, where resting retinal microg-
lia are normally located and after they are activated, they subsequently migrate to 
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the outer retinal layers [66, 69]. Another argument that HRF are in fact microglia 
is that both are primarily found in the inner retina in DR without edema and show 
an extended distribution into the outer retina in DME [68]. By contrast, Bolz et al. 
described that HRF are distributed throughout all retinal layers in eyes with dif-
ferent types of diabetic macular edema (DME), diffuse or cystoid [70]. Uji et al. 
reported the presence of HRF in the outer retina in 53.7% cases while in the inner 
retina in 99.1% cases in eyes with DME [71]. Uji et al. further suggested an origin 
from degenerated photoreceptors or macrophages engulfing the former, since HRF 
were found in the outer retina closely associated with disrupted external limiting 
membrane or IS/OS line [71].
HRF appears on OCT as small discrete, well-circumscribed, dot-shaped hyper-
reflective intraretinal lesions (Figure 1) [69]. Their size is less than 30 μm, and as 
opposed to hard exudates they do not induce back-shadowing, while their reflectiv-
ity is similar to retinal nerve fiber layer and equal or greater than the retinal pig-
ment epithelium (RPE) band [67, 72].
As opposed to HRF, hard exudates are thought to form from microaneurysms, 
which is the major source of leakage in focal edema [68]. Other theories even 
suggested that HRF can occur even before DR development, representing a neuro-
degenerative process [69]. Both the presence and number of HRF was increased in 
diabetics versus control subjects, especially in those with signs of DR, but interest-
ingly, none of the patients had signs of DME, hard exudates nor subclinical signs of 
DME on OCT examinations [68].
The size and also the number of HRF seem to decrease after treatment with 
anti-VEGF or corticosteroids [71]. The decreased microglial activity following 
anti-VEGF therapy could contribute to the reduced loads of inflammatory cyto-
kines, which further translates into decreased number of HRS and reduced CMT 
[68]. Moreover, HRS was the first feature to disappear or reduce after anti-VEGF 
therapy [66]. One study revealed that an initial presence of larger number of 
HRF responded better to dexamethasone implants than anti-VEGF therapy but a 
higher number of HRF is associated with early recurrence of DME after steroid 
implant [67].
One study found that eyes with HRF in the outer retinal layers presented 
a greater disruption in EZ (IS/OS) lines at baseline but they improved more 
than the eyes without the foci at 12 months. Taking into account this result, 
the authors further suggested that greater VA improvement could be partially 
explained by foveal photoreceptor restoration in eyes with HRF in the outer 
retinal layers [65].
Figure 1. 
Spectral domain OCT linear scan in the macula of a diabetic patient with PDR. The yellow arrows indicate 
HRF while red arrows indicate hard exudates.
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3.2.2 Sub-foveal neurosensory detachment
Hypoalbuminemia lowers the intravascular osmotic pressure and together with 
increased hydrostatic pressure can cause retention of fluid in the subretinal space. 
The role of subretinal fluid (SRF) in final visual and anatomical outcomes is still 
unclear. There is a number of studies which have shown that the presence of SRF 
is associated with good anatomical and functional gains. Contrary to this, there 
are other studies which have reported the association between the presence of 
SRF with poor visual gains [73]. Results from RESTORE study [74] and post hoc 
analysis from RISE/RIDE study [75] proved the protective role of SRF. These studies 
revealed the correlation between the presence of baseline SRF with better visual 
gains at the end of 1 year. These studies also showed a positive impact from SRF in 
response to ranibizumab therapy. Eyes with SRF seem to have increased IL-6 levels, 
which signifies active inflammation in these eyes, suggesting that inflammation has 
an important role in the development of this phenotype of DME [76]. Sonoda et al. 
found that eyes with subretinal detachment (SRD) presented increased intravit-
real levels of IL-6, IL-8 and VEGF [77]. Discontinuation of the external limiting 
membrane in the SRD type of DME induces cellular damage, which further attracts 
scavenger cells to the retina, producing IL-6 (Figure 2) [78]. The migration of 
activated microglia in the outer segments of the retinal layer could support the pro-
duction of IL-6 and subsequently the accumulation of SRF. The SRD type of DME is 
associated with an increased number of HRF and significant functional impairment 
of the macula [78]. The presence of numerous HRF is also associated with poorer 
glycemic control in patients without significant DME [79]. The levels of ICAM 1 are 
associated with the height of SRF, indicating that increased vascular permeability 
by inflammatory mediators results in SRF [80]. An important finding was that 
DME eyes with SRF respond significantly better to dexamethasone implants and 
the authors consequently supported the use of dexamethasone implants in patients 
with DME with SRF [81]. Interestingly, a recent study assessing the change of 
parameters in DME with SRD after treatment, reported that intravitreal injection 
of steroid like dexamethasone implant showed greater decrease in number of RHF 
compared to anti-VEGF agent such as ranibizumab [82].
3.2.3 Hyperreflective choroidal foci
The analysis of the choroid could be an important tool in the assessment of 
progressing DR. Choroidal parameters such as luminal area (LA), stromal area (SA) 
and total choroidal area (TCA) were found decreased in diabetic patients compared 
to control by a recent study [83]. Hyperreflective choroidal foci (HCF) is a recently 
described entity in DR. It is postulated that HCF represent HRF migrated from the 
retina, into the choroidal layers, which was permitted by ELM and EZ disruption 
(Figure 3). The hypothesis that HCF are actually migrated HRF, is supported by the 
study of Roy and al. where all 59 eyes with HCF had HRF as well and there was no 
eye which had HCF in the absence of HRF on SD-OCT [84]. Presence of HCF could 
be used as a biomarker of disease severity in eyes with DR [84]. HCF were found to 
be present significantly more in PDR eyes than NPDR eyes [67].
3.2.4 Intraretinal cystoid spaces
Inner BRB is affected by elevated levels of VEGF leading to increased vascular 
permeability, which will result in a decreased osmotic gradient, extracellular fluid 
accumulation, and cyst formation [67]. VEGF is also responsible for the depletion 
of the occludin in RPE which will further disrupt the tight junction in the outer 
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BRB [85]. Damian and al. found decreased RPE thickness in almost all quadrants 
in the PDR-DMO group as opposed to NPDR-DMO group, where the quadrants 
number was lower [86]. This finding was explained by a disruption of the RPE-
photoreceptors complex due to ischemia and level of inflammation that varies 
according to the stage of DR. Cysts larger than >200 μm in the outer nuclear layer 
(ONL) are seen in advanced stages of DME and may cause irreversible damage to 
visual functions. Due to their location, they damage photoreceptor cells and disrupt 
inner segment–outer segment (IS/OS) junction (Figure 4). Regarding their con-
tent, there is paucity of information in the literature. Liang and al. hypothesize that 
fibrin and other inflammatory cells may fill these spaces [87]. Treatment with anti-
VEGF therapy leads to a decrease in the number and size of ONL cysts by decreas-
ing the permeability of the inner BRB. This was associated with improvement in 
BCVA and microperimetric retinal sensitivity. Hyperreflective signals within the 
cyst are associated with severe disruption of the BRB [67].
3.2.5 Foveal hyperautofluorescence
Fundus autofluorescence (FAF) is a rapid, noninvasive imaging technique that 
may give new insights into the evaluation of DME. Short wavelength FAF derives 
its signal mainly from lipofuscin in the RPE. Long wavelength autofluorescence 
Figure 3. 
Spectral domain OCT linear scan in the macula of a diabetic patient with PDR. Right upper image: White-on-
black OCT scan. Right lower image: Black-on-white OCT scan. The white arrows head indicate hyperreflective 
choroidal foci. The white and black arrow highlights a group of hyperreflective retinal foci.
Figure 2. 
Spectral domain OCT linear scan in the macula of a diabetic patient with PDR. The small arrow indicates 
sub-foveal detachment. In the magnified segment of the image, the tall arrows indicate intact external limiting 
membrane (ELM) while the curly brackets indicate a discontinuous ELM.
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or near-infrared (NIR) FAF derives its signal from melanin which is present in 
RPE and choroid. Melanin accumulates in the apical parts of the RPE cells and 
is thought to protect the RPE. In DR, local ocular inflammation and oxidative 
stress lead to increased amount of lipofuscin and decreased amount of lutein and 
zeaxanthin in the macula. This is responsible for increased FAF signal in subjects 
with DME. In addition, activation of microglia in DM could cause oxidation of 
proteins and lipids. Histologic studies have found lipofuscin to accumulate in 
microglia [67].
4. Potential inflammation-targeting in diabetic retinopathy
Over the years, significant effort has been made to develop new strategies for 
the treatment of DR by targeting inflammation. Clinical and pre-clinical trials have 
tested a variety of anti-inflammatory therapeutics.
4.1 Steroids
Intravitreal injection of crystalline cortisone was first reported in 2001 by Jonas 
et al. [88]. Their mechanism of action consist in repressing pro-inflammatory 
transcription factors. Several routes of administration were tried but the oral 
steroids were avoided because of the high risk of DM exacerbation and systemic 
complications [89]. Tamura et al. found that intravitreal injection of dexametha-
sone suppresses the leukostasis, the up-regulation of ICAM-1 and also prevents 
retinal vascular leakage [90]. Since it seems to target different pathways than those 
targeted by anti-VEGF agents, corticosteroids may improve DME [91]. Especially 
DME with SRD, no HRF and a continuous ellipsoid zone at the fovea seems to 
have a better response to injectable dexamethasone implant, as shown by previous 
studies [92], explained by the increased concentrations of inflammatory cytokines 
and IL-6 found in the AH and VH of eyes with SRD. In a similar manner, intravit-
real triamcinolone has proved to be effective in the resolution of cyst in the CME 
type of DME [93]. The source of intraretinal cyst is the liquefaction and necrosis 
of Müller cells which subsequently induces the production of prostaglandins and 
inflammatory cytokines. The better outcome of steroid might be explained by the 
reduction of Müller cells’ swelling [94]. One study found better results for intravit-
real injection of triamcinolone than with anti-VEGF therapy in reducing macular 
thickness and improving BCVA in patients with SRD but the authors requested 
Figure 4. 
Spectral domain OCT linear scan in the macula of a diabetic patient with PDR. The white arrows indicate 
intraretinal cystoid spaces.
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cautious interpretation of the results because of the short follow-up (24 weeks) and 
the increased risk of associated long-term complications like cataract and elevated 
intraocular pressure [95].
4.2 NSAIDs
Their anti-inflammatory activity is characterized by inhibiting the production 
of the two isoforms of cyclooxygenase enzyme-mediated eicosanoid (COX): COX-1 
and COX-2. While COX-1 is involved in homeostatic processes, COX-2 produces 
pro-inflammatory Prostaglandins (PGE), like PGE2 and PGF2α [96]. In the retina 
of diabetic animal models, increased expression of COX-2 and PGE2 was found, 
and it seems that COX-2 has a pivotal role in DR pathogenesis since the inhibition 
of COX-2 but not COX-1 reduced the levels of PGE2 [97]. Retinal inflammatory 
reactions such as ICAM-1 expression and leukostasis were blocked after COX-2 
inhibition [98]. Aspirin, sodium salicylate and sulfasalazine prevented capillary cell 
apoptosis and vessel degeneration while COX-2 inhibitors reduced vessel degen-
eration, vascular leakage and capillary cell apoptosis [99–101]. Moreover, retinal 
microaneurysm development was decreased by high doses of aspirin (900 mg/
day), as shown by the Early Treatment DR study and the Dipyridamole Aspirin 
Microangiopathy of Diabetes Study [102, 103]. While COX-2 inhibitors have the 
potential to increase the incidence of strokes and heart attacks, their use in clinical 
trial being discouraged [104], local COX-2 inhibitors have shown reduction of DR 
sigs similar to systemic COX-2 [105].
4.3 SAR 1118
It is a small-molecule antagonist of leukocyte function-associated antigen 
(LFA)-1 a cell surface adhesion molecule of the β2 (CD18) family of integrin 
receptors expressed on leukocytes, and intercellular adhesion molecule (ICAM)-1, 
expressed by endothelial cells. SAR 1118 inhibits the binding of LFA-1, to ICAM1–1, 
being capable of preventing leukocytes adhesion to endothelial cells in vivo [106]. 
Rao et al. found that SAR 1118 eye drops significantly reduced BRB breakdown and 
leukostasis in a dose dependent manner [106].
4.4 Etanercept, infliximab
Both drugs block TNF-α induced inflammation. High dose of etanercept reduced 
leukocyte adhesion and suppressed BRB breakdown, reduced ICAM-1 expression 
but it did not reduced the expression of CD11a, CD11b and CD18, and neither 
changed the retinal vascular endothelial growth factor levels [14]. After Infliximab 
administration, BCVA improved and CMT decreased [107]. But caution should be 
taken since intravitreal use of TNF-α inhibitors has proved to induce intraocular 
inflammation [56].
4.5 Anti-CD49a neutralizing antibody
Integrin alpha 4 (CD49d), in complex with integrin beta1, forms very late 
antigen-4 (VLA-4), which interacts with vascular cell adhesion molecule-1, 
being involved in leukocyte adhesion. Iliaki et al. showed that injection of 
an anti-alpha 4 integrin/CD49d neutralizing antibody reduced the diabetes 
induced upregulation of NF- kappaB activation, VEGF, and TNF-alpha protein 
levels and significantly reduced diabetes-induced leukocyte adhesion and vascu-
lar leakage [108].
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4.6 Vitamins C and E
Another key mediator in inflammation is oxidative stress. Vitamin C attenuated 
the development of acellular capillaries [109] and vitamin E reversed some changes 
in the retinal vessels of diabetic patients [110].
4.7 Soluble RAGE, LR-90
The receptor for advanced glycation end products (AGEs) has been implicated in 
the pathogenesis of diabetic complications. When soluble RAGE, a competitor of cel-
lular RAGE for its ligands was administered, neuronal dysfunction and reduced devel-
opment of capillary lesions was proved by Barile et al. in mouse diabetic models [111].
4.8 Apocynin, statin
NAPDH oxidase activity blocking by apocynin reduces oxidative stress. Previous 
studies showed that by blocking NADPH oxidase, oxidative stress, retinal inflam-
mation, vessel leakage as well as neovascularization are prevented [5].
4.9 Captopril, Telmisartan, Talsartan, Olmesartan, candesartan, Enalapril
The RAS system is involved in different DR pathways, such as oxidative stress 
and AGEs. Captopril proved to inhibit capillary degeneration in early stages of DR, 
while Losartan (an AT1R blocker) and Enalapril (angiotensin converting enzyme 
inhibitor) reduced the progression of DR by 70% and 65% respectively [112]. Retinal 
adherent leukocyte was significantly suppressed by telmisartan or valsartan [113].
4.10 Plasma kallikrein inhibitors: KVD001 and THR-149
Plasma kallikrein is involved in both VEGF-mediated and VEGF-independent 
mechanisms of DME. In a Phase 1B study, KVD001, a novel intravitreous plasma 
kallikrein selective competitive inhibitor was administered in DME eyes [114]. The 
authors of the previous study reported that KVD001 was safe and well tolerated 
while a significant number of eyes experienced a reduction of CRT (central retinal 
thickness) and BCVA improvement. Another recent Phase 2A study evaluated 
patients who received either a sham, a high dose or a low dose of 4 intravitreal 
injections of KVD001 at monthly intervals [115]. There were no statistical differ-
ences between the number of gained letters, neither regarding the central subfield 
thickness (CST) nor the diabetic retinopathy severity scale (DRSS) but only 32.5% 
of patients from the 6 μg dose group experienced a reduction in vision compared to 
54.5% of patients from the sham group (p = 0.042) [116]. THR-149 is a reversible 
peptide inhibitor of plasma kallikrein, by inhibiting the release of bradykinin in the 
vitreous. Since it is VEGF-independent, anti-VEGF nonresponding patients could 
benefit from its effect. A Phase 1 study in which 12 patients were followed, proved 
THR-149 is safe and well tolerated while BCVA improved since day 1 and main-
tained until month 3 [117].
5. Conclusions
In accordance with the presented studies, multiple local laboratory and imaging 
biomarkers are involved in the onset and progression of DR, which could support 
and improve the screening, treatment and follow-up of these patients.
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